Clarity Pharmaceuticals Ltd
CU6.ASXHealth Care
Clarity is a clinical stage radiopharmaceutical company developing next-generation theranostic (therapy and imaging) products, based on its platform SAR Technology.
Market Data
$2.360
+0.1%$832.0M
-100000.0x
$-0.279
0.00%
-0.4%
Recent Announcements
Ceasing to be a substantial holder
JPMorgan Chase & Co. and its affiliates ceased to be a substantial holder.
Ceasing to be a substantial holder
Vanguard Group (The Vanguard Group, Inc. ceased to be a substantial holder.
Becoming a substantial holder
JPMorgan Chase & Co. and its affiliates became a substantial holder (5.14%).
Ceasing to be a substantial holder
Regal Partners Funds Management Pty Ltd and its ceased to be a substantial holder.
Ceasing to be a substantial holder
State Street Corporation ceased to be a substantial holder.
Becoming a substantial holder
State Street Corporation became a substantial holder (5.12%).
Ceasing to be a substantial holder
Citigroup Global Markets Australia Pty Limited (ACN 003 114 832) ceased to be a substantial holder.
Becoming a substantial holder
Citigroup Global Markets Australia Pty Limited (ACN 003 114 832) became a substantial holder (5.0305%).
Becoming a substantial holder
Vanguard Group (The Vanguard Group, Inc. became a substantial holder (5.007%).
Get real-time alerts for CU6
Receive AI-powered earnings summaries and instant notifications when Clarity Pharmaceuticals Ltd releases results.
Register Free